In 2024, the FDA approved two mAbs to prevent or reduce bleeding episodes related to hemophilia A and B. The first, marstacimab, which was approved on 11 October, is a human IgG1 mAb that targets tissue factor pathway inhibitor (TFPI). Here, TFPI is linked to hemophilia A.